JP2023505543A5 - - Google Patents

Info

Publication number
JP2023505543A5
JP2023505543A5 JP2022534860A JP2022534860A JP2023505543A5 JP 2023505543 A5 JP2023505543 A5 JP 2023505543A5 JP 2022534860 A JP2022534860 A JP 2022534860A JP 2022534860 A JP2022534860 A JP 2022534860A JP 2023505543 A5 JP2023505543 A5 JP 2023505543A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
poloxamer
composition according
polyethylene glycol
cabotegravir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022534860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505543A (ja
JP7703538B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/061582 external-priority patent/WO2021116872A1/en
Publication of JP2023505543A publication Critical patent/JP2023505543A/ja
Publication of JP2023505543A5 publication Critical patent/JP2023505543A5/ja
Application granted granted Critical
Publication of JP7703538B2 publication Critical patent/JP7703538B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022534860A 2019-12-09 2020-12-07 カボテグラビルを含んでなる医薬組成物 Active JP7703538B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962945412P 2019-12-09 2019-12-09
US62/945,412 2019-12-09
US202062982305P 2020-02-27 2020-02-27
US62/982,305 2020-02-27
PCT/IB2020/061582 WO2021116872A1 (en) 2019-12-09 2020-12-07 Pharmaceutical compositions comprising cabotegravir

Publications (3)

Publication Number Publication Date
JP2023505543A JP2023505543A (ja) 2023-02-09
JP2023505543A5 true JP2023505543A5 (cg-RX-API-DMAC7.html) 2023-12-15
JP7703538B2 JP7703538B2 (ja) 2025-07-07

Family

ID=73834567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534860A Active JP7703538B2 (ja) 2019-12-09 2020-12-07 カボテグラビルを含んでなる医薬組成物

Country Status (14)

Country Link
US (1) US20230045509A1 (cg-RX-API-DMAC7.html)
EP (1) EP4072520B1 (cg-RX-API-DMAC7.html)
JP (1) JP7703538B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220112771A (cg-RX-API-DMAC7.html)
CN (1) CN114786648A (cg-RX-API-DMAC7.html)
AU (1) AU2020402659A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022010574A2 (cg-RX-API-DMAC7.html)
CA (1) CA3164528A1 (cg-RX-API-DMAC7.html)
ES (1) ES3051362T3 (cg-RX-API-DMAC7.html)
IL (1) IL293566A (cg-RX-API-DMAC7.html)
MX (1) MX2022006940A (cg-RX-API-DMAC7.html)
TW (1) TW202135815A (cg-RX-API-DMAC7.html)
UY (1) UY38982A (cg-RX-API-DMAC7.html)
WO (1) WO2021116872A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
WO2021070054A1 (en) * 2019-10-08 2021-04-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2021176366A1 (en) * 2020-03-06 2021-09-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US12703699B2 (en) 2020-03-06 2026-08-11 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
KR102987126B1 (ko) * 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
EP4135702B1 (en) * 2020-04-15 2026-06-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20230321089A1 (en) 2020-09-01 2023-10-12 Viiv Healthcare Company Combination of cabotegravir and levonorgestrel
JP2024500322A (ja) * 2020-12-07 2024-01-09 ヴィーブ、ヘルスケア、カンパニー 併用療法
IL313306A (en) * 2021-12-17 2024-08-01 Viiv Healthcare Co Combined treatments for HIV infections and their uses
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
US20250099464A1 (en) 2023-09-27 2025-03-27 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
AU2023466962A1 (en) * 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
WO2025128498A1 (en) * 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2025181723A1 (en) 2024-03-01 2025-09-04 ViiV Healthcare UK (No.3) Limited Dosing regimen

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
DK3187225T3 (da) 2005-04-28 2022-02-28 Viiv Healthcare Co Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
TWI577377B (zh) * 2010-09-16 2017-04-11 Viiv醫療保健公司 醫藥組合物
WO2015127437A1 (en) * 2014-02-24 2015-08-27 The Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
MX374543B (es) * 2014-04-11 2025-03-06 Viiv Healthcare Uk No 4 Ltd Triterpenoides con actividad inhibidora de la maduración del virus de inmunodeficiencia humana, sustituidos en la posición 3 con un anillo no aromático que lleva un sustituyente haloalquilo.
EA201790495A1 (ru) 2014-09-26 2017-09-29 Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед Фармацевтические композиции длительного действия
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
AU2017218800B2 (en) * 2016-02-12 2022-09-22 Cipla Limited Pharmaceutical compositions comprising an anti-retroviral drug and a pharmacokinetic enhancer
JP7160466B2 (ja) * 2016-06-23 2022-10-25 ヴィーブ ヘルスケア カンパニー 治療薬の送達のための組成物及び方法
WO2018002902A1 (en) * 2016-07-01 2018-01-04 Glaxosmithkline Intellectual Property (No.2) Limited Antibody-drug conjugates and therapeutic methods using the same
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
WO2019171285A1 (en) * 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
JP7436385B2 (ja) * 2018-04-24 2024-02-21 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド Hiv成熟阻害活性を有する化合物
CA3103522C (en) * 2018-07-16 2023-11-21 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
MA53973A (fr) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
CN118873676A (zh) * 2018-11-29 2024-11-01 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
PH12021500034A1 (en) 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
US20220211704A1 (en) * 2019-04-30 2022-07-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
EP3986561B1 (en) 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
MX2022002897A (es) * 2019-09-11 2022-05-16 Scripps Research Inst Profarmacos antivirales y formulaciones de los mismos.

Similar Documents

Publication Publication Date Title
Heuschkel et al. Microemulsions—modern colloidal carrier for dermal and transdermal drug delivery
HRP20250278T1 (hr) Puferovane formulacije eksendina (9-39)
Spreen et al. Long-acting injectable antiretrovirals for HIV treatment and prevention
JP2022191257A5 (cg-RX-API-DMAC7.html)
JP2022009090A5 (cg-RX-API-DMAC7.html)
JP2019503365A5 (cg-RX-API-DMAC7.html)
EP2292235A3 (de) Methotrexat-Lösungen
JP2022505928A5 (cg-RX-API-DMAC7.html)
JP2016512248A5 (cg-RX-API-DMAC7.html)
JP2017031213A5 (cg-RX-API-DMAC7.html)
JP2018048179A5 (cg-RX-API-DMAC7.html)
RU2012157805A (ru) Способы лечения рака мочевого пузыря
JP2005343897A5 (cg-RX-API-DMAC7.html)
RU2016119746A (ru) Стабильный состав инсулина глулизин
RU2017132877A (ru) Комбинация антагониста pd-1 и эрибулина для лечения рака
JP2015525763A5 (cg-RX-API-DMAC7.html)
JP2019524893A (ja) エダラボン・(+)−2−ボルネオールの舌下投与用医薬組成物
CN108884053A (zh) 预防和/或治疗与衰老有关的认知障碍和神经炎症的方法
JP2017528497A5 (cg-RX-API-DMAC7.html)
JP2015537009A5 (cg-RX-API-DMAC7.html)
TW202523329A (zh) 阿立哌唑注射用製劑之投予方法
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
RU2014113941A (ru) Суспензия для перорального введения
JP2016537364A5 (cg-RX-API-DMAC7.html)
JP2019507174A5 (cg-RX-API-DMAC7.html)